StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)

Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –

Halozyme Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Halozyme Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $818.60M, up 49.4% year over year. For fiscal 2025 it was $651.56M, up 36.0% from the year before. The highest annual figure on record is $651.56M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$651.56M+36.0%
FY2024Dec 31, 2024$479.06M+23.3%
FY2023Dec 31, 2023$388.57M+61.8%
FY2022Dec 31, 2022$240.11M-19.8%
FY2021Dec 31, 2021$299.44M+440.0%
FY2020Dec 31, 2020$55.45M–
FY2019Dec 31, 2019-$85.42M–
FY2018Dec 31, 2018-$49.50M-136.9%
FY2017Dec 31, 2017$134.05M–
FY2016Dec 31, 2016-$50.38M–
FY2015Dec 31, 2015-$37.08M–
FY2014Dec 31, 2014-$47.52M–
FY2013Dec 31, 2013-$49.34M–
FY2012Dec 31, 2012-$64.28M–
FY2011Dec 31, 2011-$34.30M–
FY2010Dec 31, 2010-$45.39M–
FY2009Dec 31, 2009-$40.15M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$240.89M+141.6%
Q1 FY2026Mar 31, 2026$180.08M+16.8%
Q4 FY2025Dec 31, 2025$219.03M+22.7%
Q3 FY2025Sep 30, 2025$178.60M+54.8%
Q2 FY2025Jun 30, 2025$99.71M+78.7%
Q1 FY2025Mar 31, 2025$154.22M+19.2%
Q4 FY2024Dec 31, 2024$178.47M+74.4%
Q3 FY2024Sep 30, 2024$115.38M-12.9%
Q2 FY2024Jun 30, 2024$55.79M-16.5%
Q1 FY2024Mar 31, 2024$129.43M+48.8%
Q4 FY2023Dec 31, 2023$102.35M+24.1%
Q3 FY2023Sep 30, 2023$132.41M+90.2%
Q2 FY2023Jun 30, 2023$66.84M+66.2%
Q1 FY2023Mar 31, 2023$86.96M+81.9%
Q4 FY2022Dec 31, 2022$82.45M-0.1%
Q3 FY2022Sep 30, 2022$69.64M-42.8%
Q2 FY2022Jun 30, 2022$40.23M+9.0%
Q1 FY2022Mar 31, 2022$47.80M-18.0%
Q4 FY2021Dec 31, 2021$82.52M+62.1%
Q3 FY2021Sep 30, 2021$121.74M+1901.0%
Q2 FY2021Jun 30, 2021$36.89M+1019.9%
Q1 FY2021Mar 31, 2021$58.30M–
Q4 FY2020Dec 31, 2020$50.92M–
Q3 FY2020Sep 30, 2020$6.08M–
Q2 FY2020Jun 30, 2020$3.29M–
Q1 FY2020Mar 31, 2020-$4.84M–
Q4 FY2019Dec 31, 2019-$26.63M-354.5%
Q3 FY2019Sep 30, 2019-$29.59M–
Q2 FY2019Jun 30, 2019-$24.79M–
Q1 FY2019Mar 31, 2019-$4.42M–
Q4 FY2018Dec 31, 2018$10.46M-93.2%
Q3 FY2018Sep 30, 2018-$18.93M-193.4%
Q2 FY2018Jun 30, 2018-$18.86M–
Q1 FY2018Mar 31, 2018-$22.18M–
Q4 FY2017Dec 31, 2017$153.25M–
Q3 FY2017Sep 30, 2017$20.26M–
Q2 FY2017Jun 30, 2017-$17.00M–
Q1 FY2017Mar 31, 2017-$22.46M–
Q4 FY2016Dec 31, 2016-$15.77M–
Q3 FY2016Sep 30, 2016-$8.75M–

More Halozyme Therapeutics figures

See a number that looks wrong?